Your browser doesn't support javascript.
loading
N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.
Schlapbach, Achim; Revesz, Laszlo; Pissot Soldermann, Carole; Zoller, Thomas; Régnier, Catherine H; Bornancin, Frédéric; Radimerski, Thomas; Blank, Jutta; Schuffenhauer, Ansgar; Renatus, Martin; Erbel, Paulus; Melkko, Samu; Heng, Richard; Simic, Oliver; Endres, Ralf; Wartmann, Markus; Quancard, Jean.
Afiliação
  • Schlapbach A; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland. Electronic address: achim.schlapbach@novartis.com.
  • Revesz L; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Pissot Soldermann C; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Zoller T; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Régnier CH; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Bornancin F; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Radimerski T; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Blank J; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Schuffenhauer A; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Renatus M; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Erbel P; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Melkko S; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Heng R; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Simic O; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Endres R; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Wartmann M; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
  • Quancard J; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
Bioorg Med Chem Lett ; 28(12): 2153-2158, 2018 07 01.
Article em En | MEDLINE | ID: mdl-29759726
ABSTRACT
Starting from a weak screening hit, potent and selective inhibitors of the MALT1 protease function were elaborated. Advanced compounds displayed high potency in biochemical and cellular assays. Compounds showed activity in a mechanistic Jurkat T cell activation assay as well as in the B-cell lymphoma line OCI-Ly3, which suggests potential use of MALT1 inhibitors in the treatment of autoimmune diseases as well as B-cell lymphomas with a dysregulated NF-κB pathway. Initially, rat pharmacokinetic properties of this compound series were dominated by very high clearance which could be linked to amide cleavage. Using a rat hepatocyte assay a good in vitro-in vivo correlation could be established which led to the identification of compounds with improved PK properties.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article